A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry-Containing Regimen, Switching Them to Once-daily Selzentry (600mg qd) Plus the Same 2 NRTIs Previously Administered

Trial Profile

A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry-Containing Regimen, Switching Them to Once-daily Selzentry (600mg qd) Plus the Same 2 NRTIs Previously Administered

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Maraviroc (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications Acquired immunodeficiency syndrome; HIV-1 infections
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms SUDS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Oct 2016 Interim results (n=28) presented at the IDWeek 2016
    • 18 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top